荣泰健康(603579) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue rose by 59.49% to CNY 520,319,585.55 year-on-year[6] - Net profit attributable to shareholders increased by 131.82% to CNY 68,631,874.93 compared to the same period last year[6] - Basic earnings per share reached CNY 0.50, up 127.27% from CNY 0.22 in the previous year[6] - The diluted earnings per share increased to CNY 0.48, up 118.18% from CNY 0.22[8] - Total operating revenue for Q1 2021 reached ¥520,319,585.55, a significant increase of 59.49% compared to ¥326,233,469.82 in the same period last year[15] - The net profit for Q1 2021 reached CNY 69.04 million, compared to CNY 27.64 million in Q1 2020, representing a 150.5% increase[28] - The total profit for Q1 2021 was CNY 73.96 million, significantly higher than CNY 31.66 million in Q1 2020, marking a 133.4% increase[28] - The company's operating profit for Q1 2021 was CNY 73.88 million, compared to CNY 32.03 million in Q1 2020, reflecting a 130.5% increase[28] Cash Flow - Net cash flow from operating activities was CNY 58,917,339.02, a significant recovery from a loss of CNY 227,682,868.54 in the previous year[6] - Cash flow from operating activities improved significantly to ¥58,917,339.02, compared to a negative cash flow of ¥-227,682,868.54 in the previous period[17] - The cash flow from operating activities for Q1 2021 was CNY 58.92 million, a turnaround from a negative cash flow of CNY -227.68 million in Q1 2020[33] - The company recorded a significant increase in cash inflow from operating activities, totaling CNY 678.97 million in Q1 2021, compared to CNY 373.75 million in Q1 2020[33] - The net cash flow from operating activities for Q1 2021 was ¥44,100,250.93, recovering from a loss of ¥269,878,263.94 in the same period last year[38] Assets and Liabilities - Total assets increased by 2.20% to CNY 3,015,302,869.58 compared to the end of the previous year[6] - Non-current assets increased by 4.13% to ¥1,180,274,203.81 from ¥1,133,461,905.74[20] - Total liabilities as of March 31, 2021, were ¥1,350,255,618.23, a slight decrease from ¥1,360,869,464.67 at the end of 2020[25] - Shareholders' equity increased to ¥1,690,646,544.27 from ¥1,653,242,406.63, reflecting a growth of 2.3%[25] Shareholder Information - The number of shareholders reached 9,321 by the end of the reporting period[10] - The top three shareholders held a combined 54.43% of the shares, with Lin Qi holding 28.93%[10][11] Expenses - Operating costs increased by 61.91% to ¥363,949,991.88 from ¥224,786,854.92, primarily due to higher sales and adjustments in operating expenses[15] - Sales expenses decreased by 16.35% to ¥37,178,661.28 from ¥44,447,106.90, attributed to the reclassification of operating expenses[16] - Research and development expenses for Q1 2021 were ¥26,331,939.12, compared to ¥22,436,820.50 in Q1 2020, marking an increase of 17.5%[26] Other Financial Metrics - The weighted average return on equity increased by 2.26 percentage points to 4.06%[6] - The company reported a total of CNY 7,196,923.89 in non-recurring gains and losses for the period[9] - The company experienced a significant increase in credit impairment losses, which rose by 360.30% to ¥-9,211,394.03 from ¥-2,001,185.82[16] - The company reported a decrease in financial expenses, with a net financial cost of -¥859,304.82, compared to -¥6,890,810.55 in the previous year[26]